Registered Rwanda · Rwanda FDA

HYTAN-40

Termisartan USP 40mg

Rwanda FDA-HMP-MA-1061 Uncoated Tablets 40mg

What it does

Termisartan is a medication used to help lower blood pressure and protect kidney function.

Commonly used for: high blood pressure (hypertension), kidney disease related to diabetes

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
Rwanda FDA-HMP-MA-1061
Registration date
23/02/2024
Expiry date
22/02/2029
Status
Registered
Active ingredient
Termisartan USP 40mg
Dosage form
Uncoated Tablets
Strength
40mg
Pack size
3x10 Tablets
Therapeutic class
-
Manufacturer / MAH
Bafna Pharmaceuticals
Applicant / LTR
PRISMA PHARMA FZE
Country of origin
INDIA
Manufacturer location
1st floor, 68, Thambu Chetty St, Parry's Corner, George Town, Chennai, Tamil Nadu 600001, India

Source: Rwanda Food and Drugs Authority · fetched 2026-03-11 22:07:20 · updated 2026-09-21 02:30:20

Disclaimer: This information is sourced from Rwanda Food and Drugs Authority (Rwanda). Always consult a qualified healthcare professional before using any medication.

About this medicine

Termisartan is a medication used to help lower blood pressure and protect kidney function.

What it treats

  • high blood pressure (hypertension)
  • kidney disease related to diabetes

How it works

Termisartan works by relaxing blood vessels, which helps to lower blood pressure and improve blood flow.

Who it's for

This medication is for adults who need help controlling their blood pressure or protecting their kidneys.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: termisartan

Telmisartan is an angiotensin II receptor antagonist (ARB) used primarily for the treatment of hypertension and for cardiovascular risk reduction in certain populations. It works by blocking the action of angiotensin II, a potent vasoconstrictor, leading to vasodilation and a subsequent decrease in blood pressure.

Indications

  • Hypertension
  • Cardiovascular risk reduction in patients unable to take ACE inhibitors
  • Heart failure

Dosage

Children: Refer to the BNF for Children for appropriate dosing in pediatric patients.

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated.

Mechanism of action

Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, inhibiting the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in lowered blood pressure and reduced workload on the heart.

Pharmacodynamics

Telmisartan decreases plasma aldosterone levels, which leads to increased sodium and water excretion. Its antihypertensive effects are typically observed within 3 hours after oral administration, with peak effects occurring around 4 to 6 hours post-dose. The antihypertensive action is maintained over 24 hours.

Pharmacokinetics

Telmisartan is well absorbed after oral administration, with a bioavailability of about 50%. It is highly protein-bound (approximately 99.5%) and has a volume of distribution of about 15 liters. The drug undergoes minimal hepatic metabolism, primarily through glucuronidation, and is excreted mainly in the feces. The elimination half-life is approximately 24 hours, allowing for once-daily dosing.

Contra-indications

  • Hypersensitivity to telmisartan or any of the excipients
  • Pregnancy
  • Severe hepatic impairment
  • Biliary obstructive disorders
  • Severe renal impairment or renal artery stenosis

Adverse effects

  • Dizziness
  • Fatigue
  • Hypotension
  • Hyperkalemia
  • Renal impairment
  • Angioedema
  • Gastrointestinal disturbances

Interactions

  • Other antihypertensive agents may enhance the hypotensive effect
  • Potassium-sparing diuretics or potassium supplements may increase the risk of hyperkalemia
  • NSAIDs may reduce the antihypertensive effect
  • Lithium levels may increase when combined with telmisartan

Precautions

  • Monitor renal function before and during treatment
  • Caution in patients with a history of angioedema
  • Use with caution in patients with heart failure or aortic stenosis
  • Regular monitoring of potassium levels is advised

Pregnancy

Telmisartan is contraindicated in pregnancy due to potential harm to the fetus.

Breast-feeding

It is not known if telmisartan is excreted in human milk, use with caution.

Storage

Store at room temperature, away from moisture and heat.

Formulations

  • Tablets: 20 mg, 40 mg, 80 mg

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.